10/07/2022 /
The scientific community should develop standardized seizure first aid training programs for the general public and healthcare professionals alike.
10/07/2022 /
Epilepsy is a chronic neurological disorder and there is increasing evidence about the role of inflammation in epileptogenesis. These findings have spurred the search for new immunomodulatory approaches that can improve prognosis.
10/06/2022 /
Donation match through Oct. 16, free webinars, Seizing Life’s 100th episode, and more in this Update!
10/04/2022 /
A new study will use long term seizure tracking technology to monitor and potentially predict patterns in epileptic seizures using continuous data collection of brain activity in people with drug-resistant epilepsy.
10/03/2022 /
The current evidence supporting the use of vagus nerve stimulation in patients with therapy resistant epilepsy after new-onset refractory status epilepticus warrants further investigation.The current evidence supporting the use of vagus nerve stimulation in patients with therapy resistant epilepsy after new-onset refractory status epilepticus warrants further investigation.
09/30/2022 /
CNB was the first drug in these patients that resulted in a long-lasting and significant seizure reduction. No severe adverse events occurred. We highlight cenobamate as an antiseizure medication that may lead to a clinically meaningful reduction of seizure frequency in adult patients with Dravet syndrome. It is, however, unclear if all patients with DS benefit, requiring further investigation and functional experiments.
09/29/2022 /
People who had bariatric surgery had a 45% increased risk of developing epilepsy compared to people who did not have bariatric surgery. People who had a stroke after their bariatric surgery were 14 times more likely to develop epilepsy than those who did not have a stroke.
09/29/2022 /
This study was carried out to determine the effect of intrauterine carbamazepine (Tegretol ®) exposure on fetal bone development during pregnancy.
09/28/2022 /
Many seizing neonates fail to respond to first-line anticonvulsant medications. Phenobarbital, an allosteric modulator of GABAA receptors, has low efficacy in treating neonatal seizures and causes neuronal apoptosis [cell death]. Yet, it is one of the most used anticonvulsants in this age group.
